Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA

doi:10.1080/19420862.2016.1227665

. 2016 Nov/Dec;8(8):1425-1434.

doi: 10.1080/19420862.2016.1227665. Epub 2016 Aug 24.

Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA

James W Larrick¹, Mark R Alfenito², Jamie K Scott³, Paul W H I Parren^{4

5}, Dennis R Burton⁶, Andrew R M Bradbury⁷, Cynthia A Lemere⁸, Anne Messer⁹, James S Huston¹⁰, Paul J Carter¹¹, Trudi Veldman¹², Kerry A Chester¹³, Janine Schuurman⁴, Gregory P Adams¹⁴, Janice M Reichert¹⁵

Affiliations

¹ a Panorama Research Institute and Velocity Pharmaceutical Development , South San Francisco , CA , USA.
² b EnGen Bio, Inc. , San Mateo , CA , USA.
³ c Simon Fraser University , Burnaby , BC , Canada.
⁴ d Genmab , Utrecht , the Netherlands.
⁵ e Leiden University Medical Center , Leiden , the Netherlands.
⁶ f The Scripps Research Institute , La Jolla , CA , USA.
⁷ g Los Alamos National Laboratory , Los Alamos , NM , USA.
⁸ h Brigham and Woman's Hospital and Harvard Medical School , Boston MA , USA.
⁹ i Regenerative Research Foundation , Rensselaer , NY , USA.
¹⁰ j Huston BioConsulting, LLC , Watertown , MA , USA.
¹¹ k Genentech, Inc. , South San Francisco , CA , USA.
¹² l AbbVie , Worcester , MA , USA.
¹³ m University College London , London , UK.
¹⁴ n Viventia Bio, Inc. , Philadelphia , PA , USA.
¹⁵ o The Antibody Society , Framingham , MA , USA.

PMID: 27557809
PMCID: PMC5098447
DOI: 10.1080/19420862.2016.1227665

Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA

James W Larrick et al. MAbs. 2016 Nov/Dec.

. 2016 Nov/Dec;8(8):1425-1434.

doi: 10.1080/19420862.2016.1227665. Epub 2016 Aug 24.

Authors

Affiliations

¹ a Panorama Research Institute and Velocity Pharmaceutical Development , South San Francisco , CA , USA.
² b EnGen Bio, Inc. , San Mateo , CA , USA.
³ c Simon Fraser University , Burnaby , BC , Canada.
⁴ d Genmab , Utrecht , the Netherlands.
⁵ e Leiden University Medical Center , Leiden , the Netherlands.
⁶ f The Scripps Research Institute , La Jolla , CA , USA.
⁷ g Los Alamos National Laboratory , Los Alamos , NM , USA.
⁸ h Brigham and Woman's Hospital and Harvard Medical School , Boston MA , USA.
⁹ i Regenerative Research Foundation , Rensselaer , NY , USA.
¹⁰ j Huston BioConsulting, LLC , Watertown , MA , USA.
¹¹ k Genentech, Inc. , South San Francisco , CA , USA.
¹² l AbbVie , Worcester , MA , USA.
¹³ m University College London , London , UK.
¹⁴ n Viventia Bio, Inc. , Philadelphia , PA , USA.
¹⁵ o The Antibody Society , Framingham , MA , USA.

PMID: 27557809
PMCID: PMC5098447
DOI: 10.1080/19420862.2016.1227665

Abstract

Antibody Engineering & Therapeutics, the largest meeting devoted to antibody science and technology and the annual meeting of The Antibody Society, will be held in San Diego, CA on December 11-15, 2016. Each of 14 sessions will include six presentations by leading industry and academic experts. In this meeting preview, the session chairs discuss the relevance of their topics to current and future antibody therapeutics development. Session topics include bispecifics and designer polyclonal antibodies; antibodies for neurodegenerative diseases; the interface between passive and active immunotherapy; antibodies for non-cancer indications; novel antibody display, selection and screening technologies; novel checkpoint modulators / immuno-oncology; engineering antibodies for T-cell therapy; novel engineering strategies to enhance antibody functions; and the biological Impact of Fc receptor engagement. The meeting will open with keynote speakers Dennis R. Burton (The Scripps Research Institute), who will review progress toward a neutralizing antibody-based HIV vaccine; Olivera J. Finn, (University of Pittsburgh School of Medicine), who will discuss prophylactic cancer vaccines as a source of therapeutic antibodies; and Paul Richardson (Dana-Farber Cancer Institute), who will provide a clinical update on daratumumab for multiple myeloma. In a featured presentation, a representative of the World Health Organization's INN expert group will provide a perspective on antibody naming. "Antibodies to watch in 2017" and progress on The Antibody Society's 2016 initiatives will be presented during the Society's special session. In addition, two pre-conference workshops covering ways to accelerate antibody drugs to the clinic and the applications of next-generation sequencing in antibody discovery and engineering will be held on Sunday December 11, 2016.

Keywords: Antibody engineering; antibody repertoire; antibody-drug conjugates; bispecific antibodies; international non-proprietary names; next-generation sequencing; reproducibility.

PubMed Disclaimer

References

1. Butler DC, Messer A. Bifunctional anti-huntington proteasome-directed intrabodies mediate efficient degradation of mutant huntington exon 1 protein fragments. PLoS One 2011; 6: e29199. - PMC - PubMed
1. Joshi SN, Butler DC, Messer A. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. mAbs 2012; 4:686–693. - PMC - PubMed
1. Lecerf J-M, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE, Messer A, Huston JS. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci USA 2001; 98:4764–69. - PMC - PubMed
1. Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci USA 2005; 102:11563–68. - PMC - PubMed
1. Snyder-Keller A, McLear JA, Hathorn T, Messer A. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J Neuropathol Exp Neurol 2010; 41:1078–85. doi: 10.1097/NEN.0b013e3181f530ec. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

[1] Butler DC, Messer A. Bifunctional anti-huntington proteasome-directed intrabodies mediate efficient degradation of mutant huntington exon 1 protein fragments. PLoS One 2011; 6: e29199. - PMC - PubMed

[2] Butler DC, Messer A. Bifunctional anti-huntington proteasome-directed intrabodies mediate efficient degradation of mutant huntington exon 1 protein fragments. PLoS One 2011; 6: e29199. - PMC - PubMed

[3] Joshi SN, Butler DC, Messer A. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. mAbs 2012; 4:686–693. - PMC - PubMed

[4] Joshi SN, Butler DC, Messer A. Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. mAbs 2012; 4:686–693. - PMC - PubMed

[5] Lecerf J-M, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE, Messer A, Huston JS. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci USA 2001; 98:4764–69. - PMC - PubMed

[6] Lecerf J-M, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE, Messer A, Huston JS. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci USA 2001; 98:4764–69. - PMC - PubMed

[7] Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci USA 2005; 102:11563–68. - PMC - PubMed

[8] Wolfgang WJ, Miller TW, Webster JM, Huston JS, Thompson LM, Marsh JL, Messer A. Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci USA 2005; 102:11563–68. - PMC - PubMed

[9] Snyder-Keller A, McLear JA, Hathorn T, Messer A. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J Neuropathol Exp Neurol 2010; 41:1078–85. doi: 10.1097/NEN.0b013e3181f530ec. - DOI - PMC - PubMed

[10] Snyder-Keller A, McLear JA, Hathorn T, Messer A. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J Neuropathol Exp Neurol 2010; 41:1078–85. doi: 10.1097/NEN.0b013e3181f530ec. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA

Affiliations

Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA

Authors

Affiliations

Abstract

Similar articles

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous